Metabolomics in pharmaceutical research and development. (December 2015)

• Record Type: Journal Article
• Authors: Puchades-Carrasco, Leonor; Pineda-Lucena, Antonio
• Is Part Of: Current opinion in biotechnology. Volume 35(2015)
• Page Start: 73
• Page End: 77
• Publication Date: 2015-12
• Subjects: Biotechnology -- Periodicals; 660.6
• DOI: 10.1016/j.copbio.2015.04.004
• Languages: English
• ISSNs: 0958-1669

Abstract

Graphical abstract: Highlights: Metabolomics provides a very powerful tool in pharmaceutical and clinical research. More effective therapies can be achieved by analyzing altered metabolic pathways. Metabolomic biomarkers will improve the personalization of treatments. Biofluids can facilitate the diagnosis and the evaluation of treatment response. Abstract : Metabolomics has significant potential in pharmaceutical and clinical research, including the identification of new targets, the elucidation of the mechanism of action of new drugs, the characterization of safety and efficacy profiles, as well as the discovery of biomarkers for early disease diagnosis, prognosis, patient stratification, and treatment response monitorization. Metabolomics involves the analysis of small molecules and can lead to an improved understanding of drug candidate actions and to a better selection of targets. Although the application of metabolomics in the pharmaceutical industry is still at its infancy, this experimental approach has the possibility to transform our knowledge of drug action through the examination of drug-induced metabolic pathways associated to both drug efficacy and adverse drug reactions.